The vagus nerve is the lungs’ primary neural regulator. Its sensory fibres detect stretch, irritants, and inflammatory signals throughout the airways, while its motor fibres control bronchial smooth muscle tone, mucus secretion, and the cough reflex. This vagal network explains why conditions from asthma to chronic cough are fundamentally disorders of vagal airway control — and why treatments targeting the vagus nerve are being investigated for respiratory disease.

Vagal Airway Innervation

The vagus nerve supplies approximately 80% of the parasympathetic innervation to the lungs. Its airway-related branches include the recurrent laryngeal nerve (controlling the larynx and vocal cords), bronchial branches (innervating airway smooth muscle and glands), and pulmonary plexus fibres (reaching the lung parenchyma).

Vagal sensory fibres in the airways fall into several functional types. Slowly adapting stretch receptors (SARs), located in airway smooth muscle, respond to lung inflation and mediate the Hering-Breuer reflex — the reflex that inhibits further inhalation when the lungs are fully expanded, preventing over-distension. Rapidly adapting receptors (RARs) respond to mechanical irritation, inhaled particles, and inflammatory mediators, triggering defensive reflexes including cough, bronchoconstriction, and mucus secretion. C-fibre afferents are unmyelinated sensory fibres sensitive to chemical irritants, inflammatory mediators (prostaglandins, bradykinin, capsaicin), and temperature changes — they drive the urge to cough, airway inflammation reflexes, and the sensation of chest tightness.

On the motor side, vagal efferent fibres release acetylcholine onto muscarinic M3 receptors on airway smooth muscle, causing bronchoconstriction. They also stimulate M3 receptors on submucosal glands, promoting mucus secretion. This parasympathetic bronchoconstrictor tone is present at baseline — even in healthy individuals, the airways are maintained in a mildly constricted state by tonic vagal output, which is why anticholinergic drugs can produce modest bronchodilation even in people without airway disease.

The Vagus in Asthma

Asthma involves an exaggerated vagal bronchoconstrictor response. When allergens, irritants, or inflammatory mediators activate vagal sensory fibres (particularly RARs and C-fibres), the reflex arc through the brainstem triggers excessive acetylcholine release, producing bronchospasm, mucus hypersecretion, and the characteristic wheeze and breathlessness of an asthma attack.

This understanding has shaped asthma pharmacotherapy. Anticholinergic bronchodilators — particularly long-acting muscarinic antagonists (LAMAs) like tiotropium — block the M3 receptors that mediate vagally driven bronchoconstriction. Tiotropium is now recommended as add-on therapy for patients whose asthma is not adequately controlled by inhaled corticosteroids and long-acting beta-agonists, reflecting recognition that the vagal component of asthma is clinically important and pharmacologically targetable.

More direct vagal interventions are being explored. A 2025 systematic review in Frontiers in Physiology examined vagus nerve stimulation for acute asthmatic bronchoconstriction. The review identified four human studies — including one randomised controlled trial of 31 patients — that tested VNS during histamine- or methacholine-induced bronchoconstriction. Results were encouraging: FEV1 improvements of 10-40% were observed, with one study reporting that 81% of participants met bronchodilator response criteria at 60 minutes. However, the authors rated the overall evidence as limited and low quality, with small sample sizes, inconsistent protocols, and lack of adequate controls. They called for double-blind, sham-controlled RCTs before VNS can be considered a viable asthma therapy.

The Vagus in COPD

In chronic obstructive pulmonary disease (COPD), vagal dysfunction contributes to the persistent airway obstruction, mucus hypersecretion, and chronic cough that define the condition. The inflammatory environment in COPD airways chronically activates vagal sensory fibres, driving sustained parasympathetic bronchoconstrictor tone and excessive mucus production.

Anticholinergic therapy is a cornerstone of COPD management. Tiotropium and other LAMAs are first-line maintenance treatments, reducing exacerbations and improving lung function by blocking vagally mediated bronchoconstriction. The UPLIFT trial — one of the largest COPD trials ever conducted — demonstrated that tiotropium sustained improvements in FEV1 over four years, reduced exacerbations by 14%, and improved quality of life compared to placebo.

More invasive vagal interventions have also been investigated. Targeted lung denervation — a bronchoscopic procedure that ablates vagal nerve fibres in the airways — has been tested in clinical trials for COPD. The AIRFLOW-2 trial evaluated this approach and showed technical feasibility and safety, though clinical benefit results were mixed. The concept is to permanently reduce vagal bronchoconstrictor tone in patients who do not respond adequately to inhaled anticholinergics.

Cough: A Vagal Reflex

Cough is the most recognisable vagal airway reflex. Vagal sensory fibres — C-fibres and RARs in the larynx, trachea, and major bronchi — detect irritants, mucus, or inflammatory signals and transmit them to the cough centre in the brainstem (the nucleus tractus solitarius). The efferent arc involves vagal motor fibres to the larynx and pharynx, plus spinal nerves to the diaphragm and abdominal muscles, producing the coordinated explosive exhalation of a cough.

Chronic cough — defined as a cough lasting more than 8 weeks — is increasingly understood as a disorder of vagal sensory hypersensitivity. The concept of “cough hypersensitivity syndrome” proposes that in chronic cough patients, vagal afferents become sensitised, responding to stimuli (temperature changes, talking, laughing, mild irritants) that would not trigger cough in healthy individuals. This parallels the central sensitisation seen in chronic pain conditions.

This understanding led to the development of gefapixant (Merck), a P2X3 receptor antagonist that blocks the ATP-sensing receptors on vagal C-fibres in the airways. Gefapixant was approved in Japan (2022) and the EU (2023) for refractory chronic cough, representing the first therapy specifically targeting the vagal sensory pathway in chronic cough. The drug reduces cough frequency by approximately 18-27% versus placebo in phase 3 trials, though its main side effect — taste disturbance (dysgeusia) — is common and limits tolerability for some patients.

Laryngeal Function: The Recurrent Laryngeal Nerve

The recurrent laryngeal nerve — a branch of the vagus — controls all intrinsic muscles of the larynx except the cricothyroid. It is responsible for vocal cord abduction (opening the airway during breathing) and adduction (closing the vocal cords during phonation and swallowing). Injury to this nerve, most commonly during thyroid or parathyroid surgery, causes vocal cord paralysis — resulting in hoarseness, breathy voice, and in bilateral cases, potential airway compromise.

The left recurrent laryngeal nerve follows a longer path than the right, looping under the aortic arch before ascending back to the larynx. This lengthy course makes it vulnerable to compression by thoracic pathology — aortic aneurysms, mediastinal tumours, and enlarged lymph nodes can all cause left vocal cord paralysis (Ortner syndrome). Unexplained hoarseness persisting more than two weeks warrants laryngoscopy to assess vocal cord function, as it may be the presenting sign of serious intrathoracic disease.

Supporting Respiratory Vagal Health

While the vagus nerve’s respiratory functions are largely involuntary, certain practices influence airway vagal tone. Diaphragmatic breathing engages the Hering-Breuer reflex and modulates vagal sensory input from the lungs. Regular aerobic exercise improves respiratory efficiency and autonomic balance. Smoking cessation reduces the chronic airway inflammation that drives vagal sensory hypersensitivity and excessive bronchoconstrictor tone.

For patients with asthma, COPD, or chronic cough, understanding the vagal contribution to their condition can inform treatment decisions — from anticholinergic inhalers that block vagal bronchoconstriction to emerging therapies that target vagal sensory pathways directly.

Want to understand how the vagus nerve influences every system in your body — from your lungs and heart to your gut and immune system? Get My Vagus Nerve & Me eBook for the complete science.

Keep reading

Vagus Nerve Stimulation and Weight Loss5 min read

Phrenic Nerve vs Vagus Nerve: Understanding the Differences14 min read

Does the Vagus Nerve Control the Rectum and Anus?3 min read